Merck KGaA (ETR:MRK)

Germany flag Germany · Delayed Price · Currency is EUR
111.70
+2.35 (2.15%)
Jun 24, 2025, 5:36 PM CET
-33.01%
Market Cap 48.56B
Revenue (ttm) 21.32B
Net Income (ttm) 2.82B
Shares Out 434.78M
EPS (ttm) 6.48
PE Ratio 17.25
Forward PE 12.49
Dividend 2.20 (2.01%)
Ex-Dividend Date Apr 28, 2025
Volume 258,052
Average Volume 317,525
Open 111.70
Previous Close 109.35
Day's Range 111.55 - 112.45
52-Week Range 108.10 - 177.00
Beta 0.64
RSI 41.47
Earnings Date Aug 7, 2025

About Merck KGaA

Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company’s Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing a... [Read more]

Sector Healthcare
Founded 1668
Employees 59,020
Stock Exchange Deutsche Börse Xetra
Ticker Symbol MRK
Full Company Profile

Financial Performance

In 2024, Merck KGaA's revenue was 21.16 billion, an increase of 0.78% compared to the previous year's 20.99 billion. Earnings were 2.78 billion, a decrease of -1.66%.

Financial Statements

News

Merck Foundation Chairman, CEO, and 14 First Ladies Inaugurate the 7th Edition of Merck Foundation First Ladies Initiative – MFFLI Summit in Dubai

Merck Foundation, the philanthropic arm of Merck KGaA Germany, conducted the 7th Edition of Merck Foundation First Ladies Initiative – MFFLI Summit 2025 on 19th and 20th June in Dubai, United Arab Emi...

5 days ago - Business Upturn

MilliporeSigma Announces Neoclease as Winner of 2025 North American Advance Biotech Grant

Winner’s lead therapy targets Parkinson’s disease; platform addresses 6,000+ genetic disorders Neoclease gains access to MilliporeSigma’s technologies and expert support to scale its AI-designed gene-...

6 days ago - Financial Post

EQS-PVR: Merck KGaA: Correction of a release from 05/06/2025 according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

EQS Voting Rights Announcement: Merck KGaA Merck KGaA: Correction of a release from 05/06/2025 according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of ...

11 days ago - Wallstreet:Online

China's Center for Drug Evaluation Accepts Merck KGaA, Darmstadt, Germany's Application for Marketing Authorization of Pimicotinib for Treatment of Tenosynovial Giant Cell Tumor

First global filing for potentially best-in-class TGCT treatment based on strong positive data from Phase 3 MANEUVER study Potential for pimicotinib to be first systemic TGCT therapy approved in China...

15 days ago - Benzinga

China's Center for Drug Evaluation Accepts Merck KGaA, Darmstadt, Germany's Application for Marketing Authorization of Pimicotinib for Treatment of Tenosynovial Giant Cell Tumor

DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that the Center for Drug Evaluation (CDE) of the China National Medical P...

15 days ago - Business Wire

China's Center for Drug Evaluation Accepts Merck's Application for Marketing Authorization of Pimicotinib for Treatment of Tenosynovial Giant Cell Tumor

DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (N...

15 days ago - Business Wire

EQS-PVR: Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

EQS Voting Rights Announcement: Merck KGaA Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 05.06.2...

19 days ago - Wallstreet:Online

SPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SpringWorks Therapeutics, Inc. - SWTX

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of SpringWorks Therapeutics, Inc. (NasdaqGS: SWTX...

21 days ago - Wallstreet:Online

Pimicotinib Demonstrates Best-in-Class Potential with Significant Efficacy and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumor

Global Phase 3 MANEUVER study of pimicotinib in tenosynovial giant cell tumor (TGCT) met the primary endpoint, demonstrating objective response rate at week 25 of 54.0% versus 3.2% for placebo (p<0.00...

27 days ago - Benzinga

Merck Foundation Chairman and CEO Meet Nigeria First Lady to Underscore Their Long-Term Commitment to Transform Patient Care Landscape in the Country

Abuja, Nigeria & Mumbai, Maharashtra, India: Merck Foundation, the philanthropic arm of Merck KGaA Germany underscored their commitment to build healthcare capacity, support girl education and break i...

4 weeks ago - Business Upturn

EMD Serono Presents Positive Phase 2 Data for Enpatoran Demonstrating Reduction in Disease Activity in Patients with Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE) with Active Lupus Rash

Cohort analyses from the WILLOW study reveal clear proof of concept in patients with CLE and SLE with active lupus rash, showing clinically meaningful improvement in disease activity at Week 16 Enpato...

4 weeks ago - Benzinga

Merck KGaA Cuts Outlook Amid Macroeconomic Challenges

The German life-sciences and electronics company slashed its full-year guidance on the back of challenging macroeconomic conditions and foreign-exchange headwinds.

5 weeks ago - WSJ

Merck KGaA strikes more cautious tone on 2025 adj profit

Germany's Merck KGaA on Thursday guided more cautiously for 2025 earnings, citing the macro-economic and geopolitical environment as well as foreign-exchange headwinds.

5 weeks ago - Reuters

Germany's Merck drops China surcharge on orders after US-China tariff deal

German healthcare and materials group Merck KGaA has dropped a surcharge on life sciences sector orders within China following the U.S.-China agreement to pause sky-high tariffs on each other, the com...

5 weeks ago - Reuters

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating SpringWorks Therapeutics, Inc. Buyout

Wilmington, Delaware--(Newsfile Corp. - April 28, 2025) - Rigrodsky Law, P.A. is investigating SpringWorks Therapeutics, Inc. ("SpringWorks") (NASDAQ: SWTX) regarding possible breaches of fiduciary du...

2 months ago - Wallstreet:Online

SWTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of SpringWorks Therapeutics, Inc. Is Fair to Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) to Merck KGaA, Darmstadt, Germany for $47.00 per share in cash is fair...

2 months ago - Wallstreet:Online

Germany's Merck Agrees to Buy US Biotech SpringWorks Therapeutics for Almost $4B

German drug company Merck KGaA said Monday it has struck a deal to buy U.S. biotech firm SpringWorks Therapeutics for around $3.9 billion, expanding its portfolio of rare disease and cancer treatments...

2 months ago - Investopedia

Wall Street Breakfast Podcast: Huawei Preps AI Chip To Challenge Nvidia: Report

Huawei preparing to test latest AI chip to challenge Nvidia (NVDA): report. Merck KGaA to buy Springworks for $3.9 billion. CrowdStrike unveils new AI agents for cybersecurity.

2 months ago - Seeking Alpha

Santé : Merck KGaA acquiert l'américain SpringWorks Therapeutics pour 3,4 milliards de dollars

Le groupe de santé allemand Merck KGaA a annoncé lundi l'achat de la société biopharmaceutique américaine SpringWorks Therapeutics, spécialisée...

2 months ago - Le Figaro

Merck KGaA (MKGAF) to Acquire SpringWorks Therapeutics for $3.9 Billion

Merck KGaA (MKGAF) to Acquire SpringWorks Therapeutics for $3.9 Billion

2 months ago - GuruFocus

Merck KGaA to Acquire SpringWorks Therapeutics for $3.9 Billion | SWTX stock news

Merck KGaA to Acquire SpringWorks Therapeutics for $3.9 Billion | SWTX stock news

2 months ago - GuruFocus